Samyang Group Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (28)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Samyang Group - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Samyang Group. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline. There are 3 cancer drugs by Samyang Group which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Samyang Group - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Samyang Group - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Samyang Group. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline. There are 3 cancer drugs by Samyang Group which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Samyang Group - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Samyang Group

  1.1 Business Overview

  1.2 Samyang Group Pipeline Overview

 

2. Samyang Group Cancer Drugs in Research Phase

  2.1 B 6122

 

3. Samyang Group Cancer Drugs in Preclinical Phase

  3.1 Anti-Cancer Polymeric Micelle Therapeutics - Samyang Biopharmaceuticals Corporation

 

4. Samyang Group Cancer Drugs in Phase-I

  4.1 Docetaxel Nanopolymeric – Samyang

 

5. Marketed Cancer Drugs by Samyang

  5.1 B 5626

  5.2 Docetaxel Polymeric Micelle – Samyang

  5.3 Paclitaxel Polymeric Micelle Formulation – Samyang

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 Imatinib – Samyang

  6.2 RNAi Therapeutics - Samyang/Takeda

  6.3 siRNA Therapeutics - BioMolecular Therapeutics

  6.4 Sirolimus Nanopolymer – Samyang

  6.5 Paclitaxel Nanopolymer – Samyang

 

7. Discontinued in Cancer Drugs in Clinical Pipeline

  7.1 Paclitaxel Controlled-Release – BTG

  7.2 Goserelin Polymeric Micelle – Samyang


Figure 1-1: Samyang Group Cancer Pipeline by Phase (%)

Figure 1-2: Samyang Group Cancer Pipeline by Phase (Number)

Figure 1-3: Samyang Group Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Samyang Group Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)